196 related articles for article (PubMed ID: 25882562)
1. Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond.
Mitra AP; Lerner SP
Urol Clin North Am; 2015 May; 42(2):201-15, viii. PubMed ID: 25882562
[TBL] [Abstract][Full Text] [Related]
2. [Recent advances in bladder urothelial carcinogenesis].
Pignot G; le Goux C; Bieche I
Bull Cancer; 2015 Dec; 102(12):1020-35. PubMed ID: 26617115
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis and diagnostics of bladder cancer.
Mitra AP; Cote RJ
Annu Rev Pathol; 2009; 4():251-85. PubMed ID: 18840072
[TBL] [Abstract][Full Text] [Related]
5. Emerging Bladder Cancer Biomarkers and Targets of Therapy.
Netto GJ; Tafe LJ
Urol Clin North Am; 2016 Feb; 43(1):63-76. PubMed ID: 26614029
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
Balar AV; Milowsky MI
Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
[TBL] [Abstract][Full Text] [Related]
7. Management of superficial and muscle-invasive urothelial cancers of the bladder.
Resnick MJ; Bassett JC; Clark PE
Curr Opin Oncol; 2013 May; 25(3):281-8. PubMed ID: 23425709
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in advanced bladder cancer: what have we learned?
Jordan EJ; Iyer G
Urol Clin North Am; 2015 May; 42(2):253-62, ix. PubMed ID: 25882566
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development.
Balar AV; Milowsky MI
Urol Clin North Am; 2015 May; 42(2):217-24, viii-ix. PubMed ID: 25882563
[TBL] [Abstract][Full Text] [Related]
10. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
Mitra AP; Datar RH; Cote RJ
J Clin Oncol; 2006 Dec; 24(35):5552-64. PubMed ID: 17158541
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways.
Wallerand H; Bernhard JC; Culine S; Ballanger P; Robert G; Reiter RE; Ferrière JM; Ravaud A
Urol Oncol; 2011; 29(1):4-11. PubMed ID: 19914099
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
14. Targeting FGFR in bladder cancer: ready for clinical practice?
De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
[No Abstract] [Full Text] [Related]
15. Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer.
Boehm BE; Svatek RS
Urol Clin North Am; 2015 May; 42(2):159-68, vii. PubMed ID: 25882558
[TBL] [Abstract][Full Text] [Related]
16. The Cancer Genome Atlas Project in Bladder Cancer.
Rodriguez-Vida A; Lerner SP; Bellmunt J
Cancer Treat Res; 2018; 175():259-271. PubMed ID: 30168126
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations associated with bladder cancer progression.
Sánchez-Carbayo M; Cordon-Cardó C
Semin Oncol; 2007 Apr; 34(2):75-84. PubMed ID: 17382791
[TBL] [Abstract][Full Text] [Related]
18. Simple and Efficient Stratification of Invasive Bladder Cancer Patients.
Zoidakis J
EBioMedicine; 2016 Oct; 12():6-7. PubMed ID: 27599968
[No Abstract] [Full Text] [Related]
19. A molecular signature in superficial bladder carcinoma predicts clinical outcome.
Dyrskjøt L; Zieger K; Kruhøffer M; Thykjaer T; Jensen JL; Primdahl H; Aziz N; Marcussen N; Møller K; Orntoft TF
Clin Cancer Res; 2005 Jun; 11(11):4029-36. PubMed ID: 15930337
[TBL] [Abstract][Full Text] [Related]
20. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
